North East and North Cumbria
ICS Formulary
 
back
9 Nutrition and blood
09-01-03 Erythropoietin

Darbepoetin Alfa Aranesp®
First Choice

  • 10, 15, 20, 30, 40, 50, 60, 80, 100, 150 & 300 microgram injections in prefilled syringes 

  • 20, 40, 60, 80, 100 & 300 microgram Sureclick® pens - approved for management of cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer 



  • Monitoring: monitoring of erythropeoetin (darbepoetin) in adult patients can be undertaken by GPs under a shared care arrangement Amber

Link  MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
Link  NICE CG114: Anaemia in chronic kidney disease
Link  NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Link  North of Tyne, Gateshead and North Cumbria - Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD)

Red View adult BNF  View SPC online  View childrens BNF  HCD
Epoetin delta
Formulary

Red View adult BNF  View SPC online  View childrens BNF
Epoetin theta
Formulary

Red View adult BNF  View SPC online  View childrens BNF
Epoetin zeta
Formulary
Link  MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

Red View adult BNF  View SPC online  View childrens BNF
Epoetin alfa Eprex®
Formulary
  • Prefilled syringes (various strengths)
    • Approved for management of cancer treatment-induced anaemia in
      women receiving platinum-based chemotherapy for ovarian cancer
    • No longer regularly used in NUTH
Link  MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
Link  NICE NG203: Chronic kidney disease: assessment and management
Link  NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Link  Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD)

Red View adult BNF  View SPC online  View childrens BNF  HCD
Epoetin beta NeoRecormon®
Formulary

  • Cartridges for use in RecopensPrefilled syringes


    • Approved for management of cancer treatment-induced anaemia
      in women receiving platinum-based chemotherapy for ovarian cancer.

    • No longer regularly used in NUTH.



  • Monitoring: monitoring of erythropeoetin (epoetin beta) in adult patients can be undertaken by GPs under a shared care arrangement Amber

Link  MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
Link  NICE NG203: Chronic kidney disease: assessment and management
Link  NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Link  Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD)

Red View adult BNF  View SPC online  View childrens BNF  HCD
Methoxy Polyethylene Glycol-Epoetin Beta Mircera®, Pegzerepoetin® alfa
Formulary
  • 30, 50, 100, 120, 150, 200 & 250 microgram in 0.3ml and 360 microgram in 0.6ml injections in prefilled syringes.
  • Approved for use as a longer-acting alternative to darbepoetin in a
    small number of patients receiving peritoneal dialysis.
Link  MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

Red View adult BNF  View SPC online  View childrens BNF  HCD